Haiyan Fu Selected Research

Mucopolysaccharidosis III (Sanfilippo Syndrome)

12/2017	Differential Prevalence of Antibodies Against Adeno-Associated Virus in Healthy Children and Patients with Mucopolysaccharidosis III: Perspective for AAV-Mediated Gene Therapy.
1/2017	Near-Complete Correction of Profound Metabolomic Impairments Corresponding to Functional Benefit in MPS IIIB Mice after IV rAAV9-hNAGLU Gene Delivery.
1/2016	Functional correction of neurological and somatic disorders at later stages of disease in MPS IIIA mice by systemic scAAV9-hSGSH gene delivery.
12/2015	A GLP-Compliant Toxicology and Biodistribution Study: Systemic Delivery of an rAAV9 Vector for the Treatment of Mucopolysaccharidosis IIIB.
4/2015	Broad functional correction of molecular impairments by systemic delivery of scAAVrh74-hSGSH gene delivery in MPS IIIA mice.
6/2014	Feasibility and safety of systemic rAAV9-hNAGLU delivery for treating mucopolysaccharidosis IIIB: toxicology, biodistribution, and immunological assessments in primates.
1/2013	Amyloidosis, synucleinopathy, and prion encephalopathy in a neuropathic lysosomal storage disease: the CNS-biomarker potential of peripheral blood.
6/2011	Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery.
3/2011	Differential distribution of heparan sulfate glycoforms and elevated expression of heparan sulfate biosynthetic enzyme genes in the brain of mucopolysaccharidosis IIIB mice.
7/2010	Mucopolysaccharidosis IIIB, a lysosomal storage disease, triggers a pathogenic CNS autoimmune response.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Haiyan Fu Research Topics

Disease

13	Mucopolysaccharidosis III (Sanfilippo Syndrome) 12/2017 - 01/2002
9	Mucopolysaccharidoses 10/2017 - 03/2009
8	Fibrosis (Cirrhosis) 01/2022 - 11/2016
8	Neoplasms (Cancer) 06/2021 - 05/2006
7	Lysosomal Storage Diseases (Lysosomal Storage Disease) 01/2017 - 03/2009
6	Sepsis (Septicemia) 12/2020 - 08/2015
6	Acute Kidney Injury (Acute Renal Failure) 01/2020 - 01/2016
5	Proteinuria 01/2022 - 10/2016
4	Chronic Renal Insufficiency 01/2022 - 01/2020
4	Albuminuria 01/2022 - 10/2016
4	Reperfusion Injury 11/2019 - 01/2018
3	Diabetic Nephropathies (Diabetic Nephropathy) 01/2022 - 10/2016
3	Kidney Diseases (Kidney Disease) 12/2020 - 02/2016
3	Disease Progression 12/2019 - 07/2010
3	Inflammation (Inflammations) 10/2019 - 11/2014
2	Carcinogenesis 06/2021 - 10/2020
2	Liver Diseases (Liver Disease) 06/2021 - 05/2019
2	Critical Illness (Critically Ill) 07/2017 - 01/2015
2	Neurologic Manifestations (Neurological Manifestations) 07/2010 - 03/2009
2	Central Nervous System Diseases (CNS Diseases) 03/2009 - 12/2003
1	Heart Failure 03/2022
1	Wilms Tumor (Wilm's Tumor) 01/2022
1	Hypertrophy 01/2022
1	Intrahepatic Cholestasis 01/2022
1	Hepatocellular Carcinoma (Hepatoma) 06/2021
1	Chronic Hepatitis B 06/2021
1	Wounds and Injuries (Trauma) 05/2020
1	Ischemia 01/2020
1	Ulcerative Colitis 10/2019
1	Epilepsy (Aura) 05/2019
1	progressive familial intrahepatic 1 Cholestasis 05/2019
1	Virus Diseases (Viral Diseases) 05/2019
1	Cholestasis 05/2019
1	Alagille Syndrome (Alagille-Watson Syndrome) 05/2019
1	Hepatolenticular Degeneration (Wilson's Disease) 05/2019
1	Hypertension (High Blood Pressure) 01/2019

Drug/Important Bio-Agent (IBA)

8	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2013
7	alpha-N-acetyl-D-glucosaminidase (alpha-N-acetylglucosaminidase)IBA 01/2017 - 01/2002
5	CateninsIBA 01/2022 - 01/2016
4	Proteins (Proteins, Gene)FDA Link 01/2022 - 04/2013
4	Peptides (Polypeptides)IBA 01/2022 - 11/2012
4	CreatinineIBA 01/2021 - 11/2016
4	GlycosaminoglycansIBA 10/2017 - 01/2002
3	TenascinIBA 01/2020 - 03/2017
3	EnzymesIBA 10/2017 - 03/2011
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 07/2017 - 07/2010
3	Acetylglucosaminidase (NAGase)IBA 01/2017 - 06/2014
2	Streptozocin (Streptozotocin)FDA Link 01/2022 - 10/2016
2	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022 - 11/2019
2	MicroRNAs (MicroRNA)IBA 06/2021 - 01/2010
2	NitrogenIBA 01/2021 - 01/2019
2	Urea (Carbamide)FDA LinkGeneric 01/2021 - 01/2019
2	Glycoproteins (Glycoprotein)IBA 01/2020 - 03/2017
2	LigandsIBA 01/2019 - 04/2013
2	Matrix Metalloproteinase 7 (Matrilysin)IBA 01/2019 - 01/2017
2	Cisplatin (Platino)FDA LinkGeneric 01/2019 - 01/2019
2	AntibodiesIBA 12/2017 - 03/2011
2	ThymalfasinIBA 06/2017 - 01/2017
2	urinastatin (MR 20)IBA 06/2017 - 01/2017
2	LipopolysaccharidesIBA 11/2016 - 08/2015
2	Indicators and Reagents (Reagents)IBA 12/2015 - 12/2003
2	SulfotransferasesIBA 08/2015 - 03/2011
2	Complement System Proteins (Complement)IBA 11/2012 - 03/2009
2	RNA-Binding Proteins (RNA-Binding Protein)IBA 05/2012 - 01/2010
1	Creatine Kinase (Creatine Phosphokinase)IBA 03/2022
1	TroponinIBA 03/2022
1	Oxygen (Dioxygen)IBA 03/2022
1	Transaminases (Aminotransferases)IBA 01/2022
1	CalciumIBA 01/2022
1	Advanced Oxidation Protein Products (AOPP)IBA 01/2022
1	podocalyxinIBA 01/2022
1	Decellularized Extracellular MatrixIBA 01/2022
1	nephrinIBA 01/2022
1	NPHS2 proteinIBA 01/2022
1	Phosphorus (Red Phosphorus)IBA 01/2022
1	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 10/2021
1	Competitive Endogenous RNAIBA 06/2021
1	triptolideIBA 01/2021
1	AlbuminsIBA 01/2021
1	ProteomeIBA 12/2020
1	Long Noncoding RNAIBA 10/2020
1	RNA (Ribonucleic Acid)IBA 10/2020
1	IntegrinsIBA 01/2020
1	Glucose (Dextrose)FDA LinkGeneric 12/2019
1	VimentinIBA 11/2019
1	TriterpenesIBA 10/2019
1	limoninIBA 10/2019
1	Oxcarbazepine (Trileptal)FDA LinkGeneric 05/2019
1	Ursodeoxycholic Acid (Urso)FDA LinkGeneric 05/2019
1	VitaminsIBA 05/2019
1	Valproic Acid (Depakote)FDA LinkGeneric 05/2019
1	Angiotensin IIIBA 01/2019
1	Folic Acid (Vitamin M)FDA LinkGeneric 01/2019
1	CollagenIBA 01/2019
1	ICG 001IBA 01/2019
1	Fibronectins (Fibronectin)IBA 01/2019

Therapy/Procedure

9	Therapeutics 01/2022 - 03/2011
4	Intravenous Injections 01/2022 - 06/2014
2	Length of Stay 01/2015 - 11/2014
2	Enteral Nutrition (Feeding, Tube) 01/2015 - 11/2014